DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Sponsor

University of California, San Francisco (Other)

Overall Status

Completed

CT.gov ID

NCT04487145

Collaborator

Yale University (Other), Makerere University (Other), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)

190

Enrollment

Locations

Arms

16.6

Actual Duration (Months)

Patients Per Site

5.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART) and HIV-uninfected children not on ART. All children will be malaria-uninfected at the time of enrollment.

Condition or Disease	Intervention/Treatment	Phase
Drug-Drug Interaction HIV Infection	Drug: Dihydroartemisinin-piperaquine	Phase 4

Detailed Description

The primary goal of the study is to assess the pharmacokinetics (PK) and safety of DP in the setting of co-administration with first-line ART regimens (EFV-, LPV/r- or DTG-based ART) in children without malaria. Up to 190 children will be enrolled in one of the 5 groups: 1, HIV-infected children age 3 - 10 years on LPV/r-based ART (n=20 for signal dose DP, 30 standard 3-dose DP). 2, HIV-infected children age 3 - 10 years on EFV-based ART (n=30), 3, HIV-infected children age 11 - 17 years on DTG-based ART (n=30), 4, HIV-uninfected children age 3-10 years (standard 3-dose DP, n=20 for PK sampling after the 1st dose DP, n=30 for sampling after the 3rd dose DP), 5, HIV-uninfected children age 11-17 years (n=30 children receiving 3-dose DP).

HIV-infected participants will be enrolled from the Baylor Uganda Center of Excellence on the Mulago Hospital Complex, Kampala, Uganda. HIV-uninfected participants will be enrolled from Masafu General Hospital (MGH) complex in Busia, and other clinics in the surrounding area. DP weight-based dosing will follow World Health Organization (WHO) Treatment Guidelines for uncomplicated malaria (April 2015). All HIV-infected participants must be stabilized (i.e. no change in regimen for at least 10 days) on EFV, LPV/r, or DTG + 2 nucleoside reverse transcriptase inhibitors (NRTI). HIV-infected children on LPV/r will be enrolled in two Phases: Phase I participants (Group L1) will receive a single dose of DP to determine the magnitude (PK and safety) of the interaction before 3 doses are evaluated, Phase II participants (Group L3) will receive a 3-dose DP regimen (which consists of 3 days of a once daily DP dose). Phase I results will inform Phase II dosing, as a lower dose of DP over 3 days may be warranted. Phase II will not begin until PK and safety results from Phase I are evaluated. Participants in L1 and L3 will be encouraged to participate sequentially in Phase I and Phase II separated by a minimum 42-day washout period; however different children may be enrolled for the 2 phases. Weight-based dose of dihydroartemisinin-piperaquine (DP): 5- <8kg, 20+160mg; 8- <11kg, 30+240mg; 11- <17kg, 40+320mg; 17- <25kg, 60+480mg; 25- <36kg, 80+640mg; 36- <60kg, 120+960mg; 60-<80kg, 160+1280mg; >80kg, 200+1600mg.

Subjects will undergo an intensive PK study sampling design, which entails multiple venous blood collections in a smaller sample of individuals to accurately estimate drug exposure over time. These studies will be conducted in both HIV-infected and HIV-uninfected participants and will allow the researchers to investigate dihydroartemisinin (DHA) and piperaquine (PQ) PK exposure in the context of EFV-, LPV/r- and DTG-based ART in HIV-uninfected children. Comparisons will be based on an intensive PK design for DP area under the concentration-time curve (AUC) estimations. A sample size of 20 children/adolescents will be needed in groups L1 and C1. A sample size of 30 will be needed for each of the other arms (D3, E3, L3, C3a, and C3b). Sampling will occur up to day 42 in the 3-dose groups given the long half-life of PQ and for 14 or 28 days in the single dose groups. The generation of an AUC will permit robust comparisons so that results will inform treatment guidelines and policy.

Study Design

Study Type:

Interventional

Actual Enrollment :

190 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This is an open-label prospective pharmacokinetic and safety study of DP and 3 different ART regimens (EFV-, LPV/r- and DTG-based ART) in non-malaria-infected 1) HIV-infected children and 2) HIV uninfected children not on ART (controls).This is an open-label prospective pharmacokinetic and safety study of DP and 3 different ART regimens (EFV-, LPV/r- and DTG-based ART) in non-malaria-infected 1) HIV-infected children and 2) HIV uninfected children not on ART (controls).

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Actual Study Start Date :

Nov 23, 2020

Actual Primary Completion Date :

Apr 11, 2022

Actual Study Completion Date :

Apr 11, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: HIV-infected children on EFV-based ART (E3) 30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Experimental: HIV-infected children on DTG-based ART (D3) 30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Experimental: HIV-infected children on LPV/r-based ART (L1) 20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Experimental: HIV-infected children on LPV/r-based ART (L3) 30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Active Comparator: HIV-uninfected children (C1) 20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Active Comparator: HIV-uninfected children (C3a) 30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ
Active Comparator: HIV-uninfected children (C3b) 30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.	Drug: Dihydroartemisinin-piperaquine It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure. Other Names: DP Duocotexin Eurartesim DHA-PQ

Outcome Measures

Primary Outcome Measures

Area under the plasma concentration versus time curve for all drug analytes [42 days]
AUC 0-8hr or AUC 0-24hr for dihydroartemisinin and AUC 0-infinity for piperaquine
Safety of single dose DP in HIV-infected children on LPV/r-based ART determined via assessment of mean change in QT intervals from baseline [28 days]
Cardiotoxicity associated with PQ is QT interval prolongation. Electrocardiogram (ECG) will be performed to provide data on QT intervals in msec.
Safety of 3-dose DP regimens determined via-assessment of mean change in QT intervals from baseline [42 days]
Safety determined via assessment of mean change in QT intervals from baseline in HIV-infected children on LPV/r- EFV-, and DTG-based ART and HIV-uninfected controls

Secondary Outcome Measures

The effects of DP on EFV pharmacokinetics as measured by mid-level of EFV [4 days]
Pre-ART sample to quantify mid-level of EFV, sampled collected via venipuncture on Day 0, 2, & 3 to allow for comparisons of EFV level.
The association of anthropomorphic indicators of malnutrition measured as weight-for age (WFA) z-score and PK exposure of DP in HIV-infected and HIV-uninfected children [42 days]
Children will be characterized as a) "stunted" but not underweight [i.e. weight for age (WFA) z-score>-2); b) underweight, but not stunted (WFA z-score ≤-2); or c) of normal nutritional status (WFA z-scores >-1).
Assess auto-induction of DHA from single dose to 3-doses [4 days]
DHA AUC after 1st dose will be compared to AUC after 3rd dose.
CYP2B6 pharmacogenetics and its impact on EFV PK. [4 days]
To assess prevalence of CYP2B6 pharmacogenetic variants and their impact on EFV PK
The association of anthropomorphic indicators of malnutrition measured as height-for-age (HFA) z-score and PK exposure of DP in HIV-infected and HIV-uninfected children [42 days]
Children will be characterized as a) "stunted" but not underweight [i.e. height for age (HFA) z-score ≤-2); b) underweight, but not stunted (HFA z-score>-2); or c) of normal nutritional status (HFA z-scores >-1).
The effects of DP on DTG pharmacokinetics as measured by trough-level (Cmin) of DTG [4 days]
Pre-ART sample to quantify trough of DTG, sampled collected via venipuncture on Day 0, 2, & 3 to allow for comparisons of DTG level.
The effects of DP on LPV/r pharmacokinetics as measured by trough-level (Cmin) of LPV/r [4 days]
Pre-ART sample to quantify trough of LPV/r, sampled collected via venipuncture on Day 0, 2, & 3 to allow for comparisons of LPV/r level.

Eligibility Criteria

Criteria

Ages Eligible for Study:

3 Years to 17 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

All participants:

Agreement to come to clinic for all follow-up PK and safety evaluations
Provision of informed consent.

HIV-infected participants:

Residency within 30km of Mulago Hospital.
Confirmed HIV infection (confirmed positive rapid HIV test or HIV RNA as per
Ugandan guidelines).
On stable EFV-, LPV/r- or DTG-based ART for at least 10 days prior to enrollment.
Age 3 - 10 years if on EFV-based ART or LPV/r-based ART.
Age 11 - 17 years if on DTG-based ART.

HIV-uninfected participants:

Residency within 30km of Masafu General Hospital
Confirmed HIV negative test (confirmed positive rapid HIV test or HIV RNA as
per Ugandan guidelines)
Age 3 - 17 years.

Exclusion Criteria:

History of significant comorbidities such as malignancy, active tuberculosis or
other active WHO stage 4 disease
Receipt of any medications known to affect CYP450 metabolism (except ART)
within 14 days of study enrolment (see 4.2.1)
Hemoglobin < 7.0 g/dL
Current malaria infection or recent treatment with antimalarials within 28 days of
enrolment.
Asymptomatic parasitemia detected by microscopy or rapid diagnostic test (RDT)
History of side effects with DP
Prior history of cardiac disease (personal or family), baseline corrected QT intervals (QTc) >450msec, or
receipt of any cardiotoxic drugs or those known to prolong QT intervals History of
significant comorbidities such as malignancy, active tuberculosis or other WHO
stage 4 disease
Weight < 6kg
HIV-infected females on DTG-based ART and age 13-17 years who are pregnant
or of childbearing potential and do not agree to consistent and reliable
contraception.

The following medications are disallowed within 3 weeks prior to receiving study drug:

Carbamazepine
Clarithromycin
Erythromycin (oral)
Ketoconazole
Phenobarbital
Phenytoin
Rifabutin
Rifampicin
Halofantrine
Any other medication known to significantly affect CYP450 metabolism.
Grapefruit juice should be avoided during the study due to its potential effects on CYP3A4.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Masafu General Hospital (MGH) at Busia District, Eastern Uganda	Masafu	Busia	Uganda
2	Baylor-Uganda Center of Excellence on Mulago Hospital Complex and Masafu General Hospital	Kampala		Uganda

Sponsors and Collaborators

University of California, San Francisco
Yale University
Makerere University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators

Principal Investigator: Francesca Aweeka, University of California, San Francisco
Principal Investigator: Sunil Parikh, Yale University
Principal Investigator: Norah Mwebaza, Makerere University
Study Chair: Adeodata Kekitiinwa, Baylor College of Medicine Children's foundation Uganda